answersLogoWhite

0

HUMIRA's primary patent expired in the United States on December 31, 2016, but the drug remained protected by additional patents until 2023. The last of these patents related to formulations and methods of use expired in 2023, which allowed for the introduction of biosimilars. Consequently, the availability of biosimilar versions of HUMIRA began in the U.S. in 2023.

User Avatar

AnswerBot

1mo ago

What else can I help you with?